European Nanomedicine Characterization Laboratory

Informazioni relative al progetto

EUNCL

ID dell’accordo di sovvenzione: 654190

DOI

10.3030/654190

Progetto chiuso

Data della firma CE 26 Giugno 2015

Data di avvio 1 Maggio 2015

Data di completamento 31 Dicembre 2019

Finanziato da

• EXCELLENT SCIENCE - Research Infrastructures

Costo totale

€ 5 627 303,50

Contributo UE

€ 4 995 181,00

Coordinato da

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
France

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

Documents, reports (27)

Liaison activities with external stakeholders –final report

A final report on the Liaison activities with external stakeholders will be prepared.

1st scientific report on Structure Activity Relationship studies
2nd report on reviews of QMS of EU-NCL
2nd scientific report on mode of action studies
Liaison activities with external stakeholders – 1st report
2nd Prioritized list of candidate technologies
3rd report on reviews of QMS of EU-NCL
1st completed survey with regulatory bodies
Activities to promote innovation through partnership with industry– 3rd report
2nd Completed survey with regulatory bodies
1st report on reviews of QMS of EU-NCL
CMS implemented
1st Data management plan
1st List of candidate technologies
2nd Data management plan
2nd report on the testing and optimization of novel technologies
1st report on modeling of analytical decision process
3rd Completed survey with regulatory bodies
3rd Data Management Plan

3rd Sample Management Report

1st report on the testing and optimization of novel technologies
Activities to promote innovation through partnership with industry – 2nd report

Activities to promote innovation through partnership with industry– 2nd report

Activities to promote innovation through partnership with industry– 1st report
2nd List of candidate technologies
2nd scientific report on Structure Activity Relationship studies
1st Prioritized list of candidate technologies
1st scientific report on mode of action studies
2nd report on modeling of analytical decision process

Websites, patent fillings, videos etc. (9)

Publication of 2nd TNA open call
EU-NCL annual workshop –year 3
Publication of 1st TNA open call
Publication of “State-of-the-art” manuscript – version 1
EU-NCL annual workshop –year 2
Publication of “State-of-the-art” manuscript – version 2
EU-NCL annual workshop – year 4
EU-NCL website
Publication of 3rd TNA open call

Demonstrators, pilots, prototypes (5)

3rd Collection of approved measurement SOPs
2nd Collection of approved measurement SOPs
1st Collection of approved measurement SOPs
Sample receiving laboratory installed
4th Collection of approved measurement SOPs

Other (3)

TNA “guide for applicant” & evaluation form
CMS developed
Appointment of the peer review evaluation board

Pubblicazioni

Peer reviewed articles (6)

Analytical ultracentrifugation for analysis of doxorubicin loaded liposomes

Autori: Dora Mehn, Patrizia Iavicoli, Noelia Cabaleiro, Sven Even Borgos, Fanny Caputo, Otmar Geiss, Luigi Calzolai, François Rossi, Douglas Gilliland
Pubblicato in: International Journal of Pharmaceutics, Numero 523/1, 2017, Pagina/e 320-326, ISSN 0378-5173
Editore: Elsevier BV
DOI: 10.1016/j.ijpharm.2017.03.046

Measuring Particle Size Distribution by Asymmetric Flow Field Flow Fractionation: A Powerful Method for the Preclinical Characterization of Lipid-Based Nanoparticles

Autori: Fanny Caputo, Amandine Arnould, Maria Bacia, Wai Li Ling, Emilie Rustique, Isabelle Texier, Adriele Prina Mello, Anne-Claude Couffin
Pubblicato in: Molecular Pharmaceutics, Numero 16/2, 2018, Pagina/e 756-767, ISSN 1543-8384
Editore: American Chemical Society
DOI: 10.1021/acs.molpharmaceut.8b01033

Are existing standard methods suitable for the evaluation of nanomedicines: some case studies

Autori: Sabrina Gioria, Fanny Caputo, Patricia Urbán, Ciarán Manus Maguire, Susanne Bremer-Hoffmann, Adriele Prina-Mello, Luigi Calzolai, Dora Mehn
Pubblicato in: Nanomedicine, Numero 13/5, 2018, Pagina/e 539-554, ISSN 1743-5889
Editore: Future Medicine Ltd.
DOI: 10.2217/nnm-2017-0338

Larger or more? Nanoparticle characterisation methods for recognition of dimers

Autori: D. Mehn, F. Caputo, M. Rösslein, L. Calzolai, F. Saint-Antonin, T. Courant, P. Wick, D. Gilliland
Pubblicato in: RSC Advances, Numero 7/44, 2017, Pagina/e 27747-27754, ISSN 2046-2069
Editore: Royal Society of Chemistry
DOI: 10.1039/c7ra02432k

Measuring particle size distribution of nanoparticle enabled medicinal products, the joint view of EUNCL and NCI-NCL. A step by step approach combining orthogonal measurements with increasing complexity

Autori: F. Caputo, J. Clogston, L. Calzolai, M. Rösslein, A. Prina-Mello
Pubblicato in: Journal of Controlled Release, Numero 299, 2019, Pagina/e 31-43, ISSN 0168-3659
Editore: Elsevier BV
DOI: 10.1016/j.jconrel.2019.02.030

Sound understanding of environmental, health and safety, clinical, and market aspects is imperative to clinical translation of nanomedicines

Autori: Matthias Rösslein, Neill J. Liptrott, Andrew Owen, Patrick Boisseau, Peter Wick, Inge K. Herrmann
Pubblicato in: Nanotoxicology, Numero 11/2, 2017, Pagina/e 147-149, ISSN 1743-5390
Editore: Informa Healthcare
DOI: 10.1080/17435390.2017.1279361

Book chapters (1)

Multiparametric Preclinical Assessment of Theranostics Materials

Autori: Adriele Prina-Mello
Pubblicato in: Handbook of Nanomaterials for Cancer Theranostics, 2018, Pagina/e 517-535, ISBN 9780-128133392
Editore: Elsevier
DOI: 10.1016/b978-0-12-813339-2.00017-7